Article | October 1, 2021

What Big CROs Don't Want You To Know About Staffing Scalability For Phase III Studies

By Joseph Arcangelo, inSeption Group

iStock-159091257 PS

There seems to be a conventional wisdom stating a Phase III study should be handled by a large CRO. After all, large CROs generally have the resources on-hand to staff such a study within the sponsor’s ambitious timeline. In fact, while this model might be advantageous for expansive studies in non-critical indications, it usually fails to meet the personnel needs of sponsors executing Phase III studies in critical indications, ranging from oncology and neurological disorders to development of orphan drugs.

Understanding the pros and cons when deciding between a large CRO and a more niche partner requires an examination of all factors affecting scale-up to a Phase III study: therapeutic area, the dynamics of business operations between large and small organizations, how such organizations scale up employee numbers, and more.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene